Regulation of androgen receptor signaling in prostate cancer

Scott M. Dehm, Donald J. Tindall

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Prostate cancer is a significant cause of morbidity and mortality worldwide. Normal prostate tissue is regulated by androgens, which activate the androgen receptor, a nuclear receptor transcription factor. Most prostate tumors retain androgen dependence, therefore, current therapies for advanced prostate cancer either reduce androgen levels or prevent binding to the androgen receptor. Despite this regimen, prostate cancer invariably progresses to a fatal, androgen-refractory state. Although these relapsed tumors are androgen independent, they are still dependent on the androgen receptor for their growth and survival. The focus of this review will be to highlight our current understanding of the mechanisms of androgen receptor activation in androgen-refractory prostate cancer. How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed.

Original languageEnglish (US)
Pages (from-to)63-74
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume5
Issue number1
DOIs
StatePublished - Feb 2005

Fingerprint

Androgen Receptors
Androgens
Prostatic Neoplasms
Prostate
Cytoplasmic and Nuclear Receptors
Neoplasms
Transcription Factors
Morbidity
Mortality
Growth

Keywords

  • Androgen receptor
  • Hormone refractory
  • Prostate cancer
  • Transcription

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Regulation of androgen receptor signaling in prostate cancer. / Dehm, Scott M.; Tindall, Donald J.

In: Expert Review of Anticancer Therapy, Vol. 5, No. 1, 02.2005, p. 63-74.

Research output: Contribution to journalArticle

Dehm, Scott M. ; Tindall, Donald J. / Regulation of androgen receptor signaling in prostate cancer. In: Expert Review of Anticancer Therapy. 2005 ; Vol. 5, No. 1. pp. 63-74.
@article{9aecbadd734e44deb6441b6f9e9abfd7,
title = "Regulation of androgen receptor signaling in prostate cancer",
abstract = "Prostate cancer is a significant cause of morbidity and mortality worldwide. Normal prostate tissue is regulated by androgens, which activate the androgen receptor, a nuclear receptor transcription factor. Most prostate tumors retain androgen dependence, therefore, current therapies for advanced prostate cancer either reduce androgen levels or prevent binding to the androgen receptor. Despite this regimen, prostate cancer invariably progresses to a fatal, androgen-refractory state. Although these relapsed tumors are androgen independent, they are still dependent on the androgen receptor for their growth and survival. The focus of this review will be to highlight our current understanding of the mechanisms of androgen receptor activation in androgen-refractory prostate cancer. How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed.",
keywords = "Androgen receptor, Hormone refractory, Prostate cancer, Transcription",
author = "Dehm, {Scott M.} and Tindall, {Donald J.}",
year = "2005",
month = "2",
doi = "10.1586/14737140.5.1.63",
language = "English (US)",
volume = "5",
pages = "63--74",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Regulation of androgen receptor signaling in prostate cancer

AU - Dehm, Scott M.

AU - Tindall, Donald J.

PY - 2005/2

Y1 - 2005/2

N2 - Prostate cancer is a significant cause of morbidity and mortality worldwide. Normal prostate tissue is regulated by androgens, which activate the androgen receptor, a nuclear receptor transcription factor. Most prostate tumors retain androgen dependence, therefore, current therapies for advanced prostate cancer either reduce androgen levels or prevent binding to the androgen receptor. Despite this regimen, prostate cancer invariably progresses to a fatal, androgen-refractory state. Although these relapsed tumors are androgen independent, they are still dependent on the androgen receptor for their growth and survival. The focus of this review will be to highlight our current understanding of the mechanisms of androgen receptor activation in androgen-refractory prostate cancer. How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed.

AB - Prostate cancer is a significant cause of morbidity and mortality worldwide. Normal prostate tissue is regulated by androgens, which activate the androgen receptor, a nuclear receptor transcription factor. Most prostate tumors retain androgen dependence, therefore, current therapies for advanced prostate cancer either reduce androgen levels or prevent binding to the androgen receptor. Despite this regimen, prostate cancer invariably progresses to a fatal, androgen-refractory state. Although these relapsed tumors are androgen independent, they are still dependent on the androgen receptor for their growth and survival. The focus of this review will be to highlight our current understanding of the mechanisms of androgen receptor activation in androgen-refractory prostate cancer. How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed.

KW - Androgen receptor

KW - Hormone refractory

KW - Prostate cancer

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=14244254699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244254699&partnerID=8YFLogxK

U2 - 10.1586/14737140.5.1.63

DO - 10.1586/14737140.5.1.63

M3 - Article

C2 - 15757439

AN - SCOPUS:14244254699

VL - 5

SP - 63

EP - 74

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -